{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:01:51Z","timestamp":1771286511990,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MMW Fortschr Med"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s15006-026-5619-2","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T23:04:05Z","timestamp":1771283045000},"page":"40-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Friedreich-Ataxie: Die h\u00e4ufigste autosomal-rezessiv vererbte Ataxie","Friedreich's ataxia: The most common autosomal recessive inherited ataxia"],"prefix":"10.1007","volume":"168","author":[{"given":"Friedrich","family":"Erdlenbruch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"5619_CR1544","doi-asserted-by":"crossref","unstructured":"Campuzano V et al. Friedreich\u2018s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271:1423-7","DOI":"10.1126\/science.271.5254.1423"},{"key":"5619_CR1548","doi-asserted-by":"crossref","unstructured":"Galea CA et al. Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia. Ann Neurol. 2016;79:485-95","DOI":"10.1002\/ana.24595"},{"key":"5619_CR1556","doi-asserted-by":"crossref","unstructured":"Reetz K et al. Friedreich\u2018s ataxia-a rare multisystem disease. Lancet Neurol. 2025;24:614-24","DOI":"10.1016\/S1474-4422(25)00175-9"},{"key":"5619_CR1562","doi-asserted-by":"crossref","unstructured":"Indelicato E et al. Predictors of Survival in Friedreich\u2018s Ataxia: A Prospective Cohort Study. Mov Disord. 2024;39:510-8","DOI":"10.1002\/mds.29687"},{"key":"5619_CR1566","doi-asserted-by":"crossref","unstructured":"Pousset F et al. A 22-Year Follow-up Study of Long-term Cardiac Outcome and Predictors of Survival in Friedreich Ataxia. JAMA Neurol. 2015;72:1334-41","DOI":"10.1001\/jamaneurol.2015.1855"},{"key":"5619_CR1570","doi-asserted-by":"crossref","unstructured":"Abeti R et al. Novel Nrf2-Inducer Prevents Mitochondrial Defects and Oxidative Stress in Friedreich\u2018s Ataxia Models. Front Cell Neurosci. 2018;12:188","DOI":"10.3389\/fncel.2018.00188"},{"key":"5619_CR1574","doi-asserted-by":"crossref","unstructured":"Lynch DR et al. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study). Ann Neurol. 2021;89:212-25","DOI":"10.1002\/ana.25934"},{"key":"5619_CR1578","doi-asserted-by":"crossref","unstructured":"Lynch DR et al. Efficacy of Omaveloxolone in Friedreich\u2018s Ataxia: Delayed-Start Analysis of the MOXIe Extension. Mov Disord. 2023;38:313-20","DOI":"10.1002\/mds.29286"},{"key":"5619_CR1582","doi-asserted-by":"crossref","unstructured":"Lynch DR et al. Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data. Ann Clin Transl Neurol. 2024;11:4-16","DOI":"10.1002\/acn3.51897"},{"key":"5619_CR1586","doi-asserted-by":"crossref","unstructured":"Gunther K et al. Safety Monitoring of Omaveloxolone in Friedreich Ataxia: Results from One Year of Clinical Treatment. Neurol Ther. 2025;14:1105-14","DOI":"10.1007\/s40120-025-00749-3"}],"container-title":["MMW - Fortschritte der Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-026-5619-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15006-026-5619-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-026-5619-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T23:04:06Z","timestamp":1771283046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.springermedizin.de\/doi\/10.1007\/s15006-026-5619-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":10,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["5619"],"URL":"https:\/\/doi.org\/10.1007\/s15006-026-5619-2","relation":{},"ISSN":["1438-3276","1613-3560"],"issn-type":[{"value":"1438-3276","type":"print"},{"value":"1613-3560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"17 February 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Der Autor wird durch die Deutsche Forschungsgemeinschaft (DFG) im Rahmen des DFG-Clinician-Scientist-Programms UMEA (FU 356\/12-2) gef\u00f6rdert.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}